News

TORONTO (February 27, 2019) – The governments of Saskatchewan, Alberta and Ontario have announced prescribing criteria for pediatric patients to qualify for public coverage of ORKAMBI on an exceptional, case-by-case basis. This announcement is the result of diligent advocacy work by Cystic Fibrosis Canada and the Canadian cystic fibrosis community. The decision comes three years after Health Canada approved the medication for use in Canada. 

TORONTO (November 27, 2018) ? With the launch of its holiday giving campaign, Tough Questions, Cystic Fibrosis Canada (CF Canada) is asking Canadians to help answer the questions that people with cystic fibrosis (CF) can’t. The fundraising campaign will feature five Canadian families and individuals affected by the fatal disease and demonstrate how a simple question can hurt to hear when the future is unknown. But Canadians can help because the answer to each question is in a cure.

TORONTO (October 17, 2018) –  Cannabis (also referred to as marijuana) has been available by prescription for a number of years in Canada, but with broader legalization, more interest has been raised on the subject.

TORONTO (October 4 , 2018) – Today, the Canadian Agency for Drugs and Technologies in Health (CADTH) has recommended that the cost of cystic fibrosis (CF) drug ORKAMBI not be covered by provincial drug programs. Cystic Fibrosis Canada wholeheartedly disagrees with the decision and cautions that this could have deadly consequences for some Canadians with CF for years to come.

TORONTO (June 19, 2018) – Cystic Fibrosis Canada national partner, CARSTAR, will fund travel and accommodations for participants of the Cystic Fibrosis Individualized Therapy (CFIT) study. With CARSTAR’s generous support, participants with cystic fibrosis (CF) from across Canada will travel to The Hospital for Sick Children in Toronto (SickKids) to take part in the ground-breaking study.

TORONTO (June 12, 2018) – Cystic Fibrosis Canada is pleased to announce its national partnership with Canadian based jewelry company, NOGU. Mario and Luca Lavorato, founders of NOGU and both diagnosed with cystic fibrosis (CF) at birth, have pledged to donate 50 percent of gross sales from the company’s Kite Collection to Cystic Fibrosis Canada.

TORONTO  (June 1, 2018) – Cystic Fibrosis Canada’s largest fundraising event, The Walk to Make Cystic Fibrosis History, will go to new heights in 2019 with a trek to Machu Picchu in Peru. The week long journey begins on May 25, 2019 and is organized through Charity Challenge, the world's leading tour operator, running overseas fundraising challenges.

May 2, 2018 (TORONTO) – Cystic Fibrosis Canada (CF Canada) is launching a national campaign this May, Cystic Fibrosis Awareness Month, to call on the government to make life-changing medications accessible for those who need it. Currently, a life-changing medication called Orkambi has the potential to benefit 2,100 of the 4,200 Canadians who live with cystic fibrosis (CF). Unfortunately, without public funding, many people with CF cannot access it despite its approval by Health Canada and doctors prescribing it.

TORONTO (April 24, 2018) — Cystic Fibrosis Canada’s (CF Canada) Board of Directors is pleased  to announce the appointment of Kelly Grover to the position of President and Chief Executive Officer (CEO) effective June 4, 2018.

Cystic Fibrosis Canada (Quebec) calls on government to help protect the health of people living with this fatal disease.

April 23, 2018 (Montreal, QC) – Cystic Fibrosis Canada is urging the Quebec government to take action to protect the health of Quebecers living with cystic fibrosis by granting them access to the life-changing medication Orkambi.